NEW YORK, NY – April 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a…
Report Further Validates Therapeutic Application of Proprietary Anavex Compounds in Multiple Neurological Diseases NEW YORK, NY – April 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time…
ANAVEX 2-73 strong reversal of memory impairment in Alzheimer’s disease model ANAVEX 3-71 strong reversal of synaptic loss in Alzheimer’s disease models NEW YORK, NY – March 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system…
NEW YORK, NY – March 19, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system (CNS) diseases, pain and various types of cancer, is pleased to announce the upcoming presentation of new data for two of its…
NEW YORK, NY –March 12, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Jacqueline French, MD, FAAN, to the Company’s Scientific Advisory Board.…
Neuroscience Letters 591 (2015) Christian Moritz, Francesco Berardi, Carmen Abate and Francesca Peri View Paper
NEW YORK, NY – March 10, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present…
NEW YORK, NY –March 5, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Corinne Lasmézas, DVM, PhD, to the Company’s Scientific Advisory Board.…
NEW YORK, NY – March 3, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 27th Annual ROTH Conference on Wednesday, March 11, 2015 at 11:00 a.m. PT in Salon 2 at the Ritz Carlton in…
Dementia news: Potential Alzheimer’s disease treatment ‘ANAVEX 2-73’ shows promising results in mouse studies Click here to read interview
